The Effects of Self-monitoring With a Mobile Application in Heart Failure



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:45 - Any
Updated:5/25/2018
Start Date:March 6, 2017
End Date:April 30, 2019
Contact:Judith Grossi
Email:jgrossi@med.umich.edu
Phone:734-232-6367

Use our guide to learn which trials are right for you!

A Patient-centered Mobile Intervention to Promote Self-management and Improve Patient Outcomes in Chronic Heart Failure

In the United States, about 40 percent of heart failure (HF) patients are readmitted within
1-year following their first admission for HF and hospitalization accounts for approximately
70 percent of the costs of HF management. As a result, the management of HF patients is
evolving from the traditional model of face-to-face follow-up visits toward a proactive
real-time technological model of assisting patients with monitoring and self-management while
in the community. The investigators plan to test the impact of a mobile application on
clinical outcomes in HF.

HF patients with a reduced ejection fraction will be randomized to the mobile application
versus placebo for 12 weeks. The mobile application will provide the participants with a
reminder to perform self-monitoring, a health status indicator and heart failure education
for self-management.

All participants will complete the Minnesota Living with Heart Failure Questionnaire and
Self-Care Heart Failure Index. Hospital admissions and mortality will also be collected.

Inclusion Criteria:

- 45 years old or older

- Left ventricular ejection fraction 40% (with left atrial size
>40mm or BNP > 200 pg/ml or NT-proBNP > 800 pg/ml)

- Admitted for acutely decompensated heart failure or recently discharged in the past 4
weeks.

- Smartphone (iOS or Android) with home wifi

Exclusion Criteria:

- Unstable coronary syndrome within 8 weeks (unstable angina, NSTEMI, STEMI)

- Primary valvular heart disease

- Known pericardial disease (Sarcoidosis, amyloidosis, rheumatoid arthritis, lupus)

- Uncorrected thyroid disease

- Advanced renal disease (dialysis or creatinine >4.0 mg/dL)

- End-stage HF (hospice candidate, home milrinone or dobutamine)

- Active cancer

- Pulmonary fibrosis

- Discharge to a setting other than home
We found this trial at
2
sites
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
(734) 936-4000
University of Michigan Health System The University of Michigan is home to one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials